UGT1A1 Genotyping
Test Code
UGT1A1
Test Synonyms
Irinotecan toxicity
Associations
Metastatic colorectal cancer
Methodology
Invader® Third Wave Technologies
CPT Codes
Please contact a client service specialist at 800.932.2943
Turnaround Time
2-3 days
Specimen Requirements
5.0 mL (min. 3.0 mL) whole blood EDTA, ACD accepted.
Specimen Stability
- Stable at 18°-25°C for 24 hours
- Stable 4°C for up to 4 days
Storage & Handling
- Ship at ambient temperature
- If shipment delayed, store at 2–8°C, and ship with cool/refrigerated pack (Do not allow cool/refrigerated pack to directly contact sample)
Causes for Rejection
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Reference Range
UGT1A1 *28 allele detected/not detected
Related Content
- CellSearch CTC Assay
- KRAS Mutation analysis
- BRAF Mutation analysis
- Microsatellite Instability by IHC
- p53 by IHC
- CA 27-29 by chemiluminescence
- CEA by chemiluminescence
Description
This test is indicated for patients with metastatic carcinoma of the colon or rectum who are candidates for first-line chemotherapy with CAMPTOSAR® (irinotecan) to assist with the identification of those patients who may be at risk for therapy-related toxicity.
References
- Food and Drug Administration; Background document on UGT1A1 polymorphisms and irinotecan toxicity
- Innocenti F et al. (2004). Genetic variants in the UDP-glucuronasyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 22(8):1382-1388.
Trademarks
Invader is a registered trademark of Third Wave Technologies, Inc., a wholly owned subsidiary of Hologic, Inc.
Camptosar is a registered trademark of Pfizer.
Camptosar is a registered trademark of Pfizer.